Skip to main content

Advertisement

Table 1 Time to resolution of all influenza-like symptoms between treatment groups

From: Inosine pranobex is safe and effective for the treatment of subjects with confirmed acute respiratory viral infections: analysis and subgroup analysis from a Phase 4, randomised, placebo-controlled, double-blind study

Group for analysis Hazard ratio (HR) 95 % CI P-value
Age Group: <50 and BMI <30 1.307 1.010–1.691 0.018
Age Group: <50 and BMI ≥30 0.782 0.429–1.426 0.370
Age Group: ≥50 and BMI <30 0.838 0.534–1.316 0.383
Age Group: ≥50 and BMI ≥30 0.879 0.445–1.736 0.683
Age Group: <50 and resolution of symptoms to "mild" or "none" 1.298 1.035–1.627 0.009
  1. The "bold data" are statisticly significant